**Supplementary Material**

***C9orf72* hexanucleotide repeat allele tagging SNPs:**

**Associations with ALS risk and longevity**

Karri Kaivola1,2\*, Matti Pirinen3,4,5, Hannu Laaksovirta2, Lilja Jansson1,2, Osma Rautila1,2, Jyrki Launes6, Laura Hokkanen6, Jari Lahti6, Johan G. Eriksson7,8,9,10, Timo E. Strandberg11,12, FinnGen, Pentti J. Tienari1,2

1. Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland

2. Department of Neurology, Helsinki University Hospital, P.O. Box 63, 00014, Helsinki, Finland

3. Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland

4. Department of Public Health, University of Helsinki, Helsinki, Finland

5. Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland

6. Department of Psychology and Logopedics, University of Helsinki, P.O. Box 21, 00014, Helsinki, Finland.

7. Folkhälsan Research Center, Helsinki, Finland

8. Singapore Institute for Clinical Sciences, Agency for Science Technology and Research, Singapore, Singapore

9. Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

10. Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland

11. University of Helsinki and Helsinki University Hospital, Helsinki, Finland

12. University of Oulu, Center for Life Course Health Research, Oulu, Finland

\*Corresponding author: Karri Kaivola, karri.kaivola@helsinki.fi

**SUPPLEMENTARY METHODS**

**Genotyping quality Control**

Genotyping data quality control was performed separately on samples processed with different arrays. First, we removed duplicated samples and related samples (proportion IBD > 0.125), samples with discordant sex information, outlying heterozygosity rate (>4SD) and > 5% missing genotype rate. In per-variant quality-control, we included variants that had a genotyping rate of > 95%, variants in HWE (p>0.000001) and minor allele count >= 3. To harmonize genotyping array data, we included only biallelic non-palindromic SNPs and set allele coding to match the reference genome so that A1 allele was always the alternative allele regardless of minor allele frequency.

**Data availability**

C9orf72 repeat lengths and genotypes used in the case-control analysis can be accessed at <https://github.com/kkaivola/C9orf72_repeat_length_genotype_data/> .

Accessing Finngen data requires permission from Finngen <https://www.finngen.fi/en> .

**FinnGen Ethics statement and materials & methods**

**Release 9**

Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/202, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 9 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7, BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), AB20-5926 and amendment #1 (April 23 2020) and it´s modification (Sep 22 2021), Biobank Borealis of Northern Finland\_2017\_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020.

**Release 10**

Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 10 include: THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7, BB2019\_8, BB2019\_26, BB2020\_1, BB2021\_65, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/150/2022 § 12, §13, §14, §15, §16, §17, §18, and §23, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB\_2021-0140, BB\_2021-0156 (August 26 2021, Feb 2 2022), BB\_2021-0169, BB\_2021-0179, BB\_2021-0161, AB20-5926 and amendment #1 (April 23 2020)and it´s modification (Sep 22 2021), Biobank Borealis of Northern Finland\_2017\_1013, 2021\_5010, 2021\_5018, 2021\_5015, 2021\_5023, 2021\_5017, 2022\_6001, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, 53§/2021, 13§/2022, 14§/2022, 15§/2022, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), §8/2021, §9/2022, §10/2022, §12/2022, §20/2022, §21/2022, §22/2022, §23/2022, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC\_2021\_1001.

**Finngen researchers**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Full Name** | **Affiliation** | **E-mail** | **Role 1** | **Role 2** |
| Aarno Palotie | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | aarno.palotie@helsinki.fi | **Steering Committee** | **Steering Committee** |
| Mark Daly | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | **Steering Committee** | **Steering Committee** |
| Bridget Riley-Gills | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | **Steering Committee** | **Pharmaceutical companies** |
| Howard Jacob | Abbvie, Chicago, IL, United States | howard.jacob@abbvie.com | **Steering Committee** | **Pharmaceutical companies** |
| Dirk Paul | Astra Zeneca, Cambridge, United Kingdom | dirk.paul@astrazeneca.com | **Steering Committee** | **Pharmaceutical companies** |
| Athena Matakidou | Astra Zeneca, Cambridge, United Kingdom | athena.x.matakidou@gsk.com | **Steering Committee** | **Pharmaceutical companies** |
| Adam Platt | Astra Zeneca, Cambridge, United Kingdom | adam.platt@astrazeneca.com | **Steering Committee** | **Pharmaceutical companies** |
| Heiko Runz | Biogen, Cambridge, MA, United States | heiko.runz@biogen.com | **Steering Committee** | **Pharmaceutical companies** |
| Sally John | Biogen, Cambridge, MA, United States | sally.john@biogen.com | **Steering Committee** | **Pharmaceutical companies** |
| George Okafo | Boehringer Ingelheim, Ingelheim am Rhein, Germany | george.okafo@boehringer-ingelheim.com | **Steering Committee** | **Pharmaceutical companies** |
| Nathan Lawless | Boehringer Ingelheim, Ingelheim am Rhein, Germany | nathan.lawless@boehringer-ingelheim.com | **Steering Committee** | **Pharmaceutical companies** |
| Heli Salminen-Mankonen | Boehringer Ingelheim, Ingelheim am Rhein, Germany | heli.salminen-mankonen@boehringer-ingelheim.com | **Steering Committee** | **Pharmaceutical companies** |
| Robert Plenge | Bristol Myers Squibb, New York, NY, United States | robert.plenge@bms.com | **Steering Committee** | **Pharmaceutical companies** |
| Joseph Maranville | Bristol Myers Squibb, New York, NY, United States | joseph.maranville@bms.com | **Steering Committee** | **Pharmaceutical companies** |
| Mark McCarthy | Genentech, San Francisco, CA, United States | mccarthy.mark@gene.com | **Steering Committee** | **Pharmaceutical companies** |
| Julie Hunkapiller | Genentech, San Francisco, CA, United States | hunkapiller.julie@gene.com | **Steering Committee** | **Pharmaceutical companies** |
| Margaret G. Ehm | GlaxoSmithKline, Collegeville, PA, United States | meg.g.ehm@gsk.com | **Steering Committee** | **Pharmaceutical companies** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Steering Committee** | **Pharmaceutical companies** |
| Simonne Longerich | Merck, Kenilworth, NJ, United States | simonne.longerich@merck.com | **Steering Committee** | **Pharmaceutical companies** |
| Caroline Fox | Merck, Kenilworth, NJ, United States | caroline.fox@merck.com | **Steering Committee** | **Pharmaceutical companies** |
| Anders Mälarstig | Pfizer, New York, NY, United States | anders.malarstig@pfizer.com | **Steering Committee** | **Pharmaceutical companies** |
| Katherine Klinger | Translational Sciences, Sanofi R&D, Framingham, MA, USA | katherine.klinger@sanofi.com | **Steering Committee** | **Pharmaceutical companies** |
| Deepak Raipal | Translational Sciences, Sanofi R&D, Framingham, MA, USA | deepak.rajpal@sanofi.com | **Steering Committee** | **Pharmaceutical companies** |
| Eric Green | Maze Therapeutics, San Francisco, CA, United States | egreen@mazetx.com | **Steering Committee** | **Pharmaceutical companies** |
| Robert Graham | Maze Therapeutics, San Francisco, CA, United States | rgraham@mazetx.com | **Steering Committee** | **Pharmaceutical companies** |
| Robert Yang | Janssen Biotech, Beerse, Belgium | ryang31@its.jnj.com | **Steering Committee** | **Pharmaceutical companies** |
| Chris O´Donnell | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | chris.odonnell@novartis.com | **Steering Committee** | **Pharmaceutical companies** |
| Tomi P. Mäkelä | HiLIFE, University of Helsinki, Finland, Finland | tomi.makela@helsinki.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Jaakko Kaprio | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | jaakko.kaprio@helsinki.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Petri Virolainen | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | petri.virolainen@tyks.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Antti Hakanen | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | antti.hakanen@tyks.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Terhi Kilpi | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | terhi.kilpi@thl.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Markus Perola | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | markus.perola@thl.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Jukka Partanen | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | jukka.partanen@veripalvelu.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Anne Pitkäranta | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | anne.pitkaranta@hus.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Taneli Raivio | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | taneli.raivio@hus.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Raisa Serpi | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | raisa.serpi@ppshp.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Tarja Laitinen | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | tarja.laitinen@pshp.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Veli-Matti Kosma | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | veli-matti.kosma@uef.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Jari Laukkanen | Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland | jari.laukkanen@ksshp.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Marco Hautalahti | FINBB - Finnish biobank cooperative | marco.hautalahti@finbb.fi | **Steering Committee** | **University of Helsinki & Biobanks** |
| Outi Tuovila | Business Finland, Helsinki, Finland | outi.tuovila@businessfinland.fi | **Steering Committee** | **Other Experts/ Non-Voting Members** |
| Raimo Pakkanen | Business Finland, Helsinki, Finland | raimo.pakkanen@businessfinland.fi | **Steering Committee** | **Other Experts/ Non-Voting Members** |
| Jeffrey Waring | Abbvie, Chicago, IL, United States | jeff.waring@abbvie.com | **Scientific Committee** | **Pharmaceutical companies** |
| Bridget Riley-Gillis | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | **Scientific Committee** | **Pharmaceutical companies** |
| Fedik Rahimov | Abbvie, Chicago, IL, United States | fedik.rahimov@abbvie.com | **Scientific Committee** | **Pharmaceutical companies** |
| Ioanna Tachmazidou | Astra Zeneca, Cambridge, United Kingdom | ioanna.tachmazidou@astrazeneca.com | **Scientific Committee** | **Pharmaceutical companies** |
| Chia-Yen Chen | Biogen, Cambridge, MA, United States | chiayen.chen@biogen.com | **Scientific Committee** | **Pharmaceutical companies** |
| Heiko Runz | Biogen, Cambridge, MA, United States | heiko.runz@biogen.com | **Scientific Committee** | **Pharmaceutical companies** |
| Zhihao Ding | Boehringer Ingelheim, Ingelheim am Rhein, Germany | zhihao.ding@boehringer-ingelheim.com | **Scientific Committee** | **Pharmaceutical companies** |
| Marc Jung | Boehringer Ingelheim, Ingelheim am Rhein, Germany | marc\_oliver.jung@boehringer-ingelheim.com | **Scientific Committee** | **Pharmaceutical companies** |
| Shameek Biswas | Bristol Myers Squibb, New York, NY, United States | Shameek.Biswas@bms.com | **Scientific Committee** | **Pharmaceutical companies** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Scientific Committee** | **Pharmaceutical companies** |
| Julie Hunkapiller | Genentech, San Francisco, CA, United States | hunkapiller.julie@gene.com | **Scientific Committee** | **Pharmaceutical companies** |
| Margaret G. Ehm | GlaxoSmithKline, Collegeville, PA, United States | meg.g.ehm@gsk.com | **Scientific Committee** | **Pharmaceutical companies** |
| David Pulford | GlaxoSmithKline, Stevenage, United Kingdom | david.x.pulford@gsk.com | **Scientific Committee** | **Pharmaceutical companies** |
| Neha Raghavan | Merck, Kenilworth, NJ, United States | neha.raghavan@merck.com | **Scientific Committee** | **Pharmaceutical companies** |
| Adriana Huertas-Vazquez | Merck, Kenilworth, NJ, United States | adriana.huertas.vazquez@merck.com | **Scientific Committee** | **Pharmaceutical companies** |
| Jae-Hoon Sul | Merck, Kenilworth, NJ, United States | jae.hoon.sul@merck.com | **Scientific Committee** | **Pharmaceutical companies** |
| Anders Mälarstig | Pfizer, New York, NY, United States | anders.malarstig@pfizer.com | **Scientific Committee** | **Pharmaceutical companies** |
| Xinli Hu | Pfizer, New York, NY, United States | xinli.hu@pfizer.com | **Scientific Committee** | **Pharmaceutical companies** |
| Katherine Klinger | Translational Sciences, Sanofi R&D, Framingham, MA, USA | katherine.klinger@sanofi.com | **Scientific Committee** | **Pharmaceutical companies** |
| Robert Graham | Maze Therapeutics, San Francisco, CA, United States | rgraham@mazetx.com | **Scientific Committee** | **Pharmaceutical companies** |
| Eric Green | Maze Therapeutics, San Francisco, CA, United States | egreen@mazetx.com | **Scientific Committee** | **Pharmaceutical companies** |
| Sahar Mozaffari | Maze Therapeutics, San Francisco, CA, United States | smozaffari@mazetx.com | **Scientific Committee** | **Pharmaceutical companies** |
| Dawn Waterworth | Janssen Research & Development, LLC, Spring House, PA, United States | dwaterwo@its.jnj.com | **Scientific Committee** | **Pharmaceutical companies** |
| Nicole Renaud | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | nicole.renaud@novartis.com | **Scientific Committee** | **Pharmaceutical companies** |
| Ma´en Obeidat | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | maen.obeidat@novartis.com | **Scientific Committee** | **Pharmaceutical companies** |
| Samuli Ripatti | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | samuli.ripatti@helsinki.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Johanna Schleutker | Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland | johanna.schleutker@utu.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Markus Perola | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | markus.perola@thl.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Mikko Arvas | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | mikko.arvas@veripalvelu.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Olli Carpén | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | olli.carpen@helsinki.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Reetta Hinttala | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | reetta.hinttala@oulu.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Johannes Kettunen | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | johannes.kettunen@oulu.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Arto Mannermaa | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | arto.mannermaa@uef.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Katriina Aalto-Setälä | Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland | katriina.aalto-setala@tuni.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Mika Kähönen | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | mika.kahonen@uta.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Jari Laukkanen | Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland | jari.laukkanen@ksshp.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Johanna Mäkelä | FINBB - Finnish biobank cooperative | johanna.makela@finbb.fi | **Scientific Committee** | **University of Helsinki & Biobanks** |
| Reetta Kälviäinen | Northern Savo Hospital District, Kuopio, Finland | reetta.kalviainen@kuh.fi | **Clinical Groups** | **Neurology Group** |
| Valtteri Julkunen | Northern Savo Hospital District, Kuopio, Finland | valtteri.julkunen@kuh.fi | **Clinical Groups** | **Neurology Group** |
| Hilkka Soininen | Northern Savo Hospital District, Kuopio, Finland | hilkka.soininen@uef.fi | **Clinical Groups** | **Neurology Group** |
| Anne Remes | Northern Ostrobothnia Hospital District, Oulu, Finland | anne.remes@oulu.fi | **Clinical Groups** | **Neurology Group** |
| Mikko Hiltunen | University of Eastern Finland, Kuopio, Finland | mikko.hiltunen@uef.fi | **Clinical Groups** | **Neurology Group** |
| Jukka Peltola | Pirkanmaa Hospital District, Tampere, Finland | jukka.peltola@pshp.fi | **Clinical Groups** | **Neurology Group** |
| Minna Raivio | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | minna.raivio@geri.fi | **Clinical Groups** | **Neurology Group** |
| Pentti Tienari | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | pentti.tienari@hus.fi | **Clinical Groups** | **Neurology Group** |
| Juha Rinne | Hospital District of Southwest Finland, Turku, Finland | juha.rinne@tyks.fi | **Clinical Groups** | **Neurology Group** |
| Roosa Kallionpää | Hospital District of Southwest Finland, Turku, Finland | roosa.kallionpaa@tyks.fi | **Clinical Groups** | **Neurology Group** |
| Juulia Partanen | Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland | juulia.partanen@helsinki.fi | **Clinical Groups** | **Neurology Group** |
| Ali Abbasi | Abbvie, Chicago, IL, United States | ali.abbasi@abbvie.com | **Clinical Groups** | **Neurology Group** |
| Adam Ziemann | Abbvie, Chicago, IL, United States | adam.ziemann@abbvie.com | **Clinical Groups** | **Neurology Group** |
| Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | **Clinical Groups** | **Neurology Group** |
| Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | **Clinical Groups** | **Neurology Group** |
| Susan Eaton | Biogen, Cambridge, MA, United States | susan.eaton@biogen.com | **Clinical Groups** | **Neurology Group** |
| Heiko Runz | Biogen, Cambridge, MA, United States | heiko.runz@biogen.com | **Clinical Groups** | **Neurology Group** |
| Sanni Lahdenperä | Biogen, Cambridge, MA, United States | sanni.lahdenpera@biogen.com | **Clinical Groups** | **Neurology Group** |
| Shameek Biswas | Bristol Myers Squibb, New York, NY, United States | shameek.biswas@bms.com | **Clinical Groups** | **Neurology Group** |
| Julie Hunkapiller | Genentech, San Francisco, CA, United States | hunkapiller.julie@gene.com | **Clinical Groups** | **Neurology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Neurology Group** |
| Edmond Teng | Genentech, San Francisco, CA, United States | teng.edmond@gene.com | **Clinical Groups** | **Neurology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Neurology Group** |
| Fanli Xu | GlaxoSmithKline, Brentford, United Kingdom | chun-fang.2.xu@gsk.com | **Clinical Groups** | **Neurology Group** |
| David Pulford | GlaxoSmithKline, Stevenage, United Kingdom | david.x.pulford@gsk.com | **Clinical Groups** | **Neurology Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Neurology Group** |
| Laura Addis | GlaxoSmithKline, Brentford, United Kingdom | laura.x.addis@gsk.com | **Clinical Groups** | **Neurology Group** |
| John Eicher | GlaxoSmithKline, Brentford, United Kingdom | john.d.eicher@gsk.com | **Clinical Groups** | **Neurology Group** |
| Qingqin S Li | Janssen Research & Development, LLC, Titusville, NJ 08560, United States | QLi2@its.jnj.com | **Clinical Groups** | **Neurology Group** |
| Karen He | Janssen Research & Development, LLC, Spring House, PA, United States | khe2@its.jnj.com | **Clinical Groups** | **Neurology Group** |
| Ekaterina Khramtsova | Janssen Research & Development, LLC, Spring House, PA, United States | ekhramts@its.jnj.com | **Clinical Groups** | **Neurology Group** |
| Neha Raghavan | Merck, Kenilworth, NJ, United States | neha.raghavan@merck.com | **Clinical Groups** | **Neurology Group** |
| Martti Färkkilä | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | martti.farkkila@hus.fi | **Clinical Groups** | **Gastroenterology Group** |
| Jukka Koskela | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | jukka.koskela@helsinki.fi | **Clinical Groups** | **Gastroenterology Group** |
| Sampsa Pikkarainen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | sampsa.pikkarainen@hus.fi | **Clinical Groups** | **Gastroenterology Group** |
| Airi Jussila | Pirkanmaa Hospital District, Tampere, Finland | airi.jussila@pshp.fi | **Clinical Groups** | **Gastroenterology Group** |
| Katri Kaukinen | Pirkanmaa Hospital District, Tampere, Finland | katri.kaukinen@tuni.fi | **Clinical Groups** | **Gastroenterology Group** |
| Timo Blomster | Northern Ostrobothnia Hospital District, Oulu, Finland | timo.blomster@ppshp.fi | **Clinical Groups** | **Gastroenterology Group** |
| Mikko Kiviniemi | Northern Savo Hospital District, Kuopio, Finland | mikko.kiviniemi@kuh.fi | **Clinical Groups** | **Gastroenterology Group** |
| Markku Voutilainen | Hospital District of Southwest Finland, Turku, Finland | markku.voutilainen@tyks.fi | **Clinical Groups** | **Gastroenterology Group** |
| Mark Daly | Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | **Clinical Groups** | **Gastroenterology Group** |
| Ali Abbasi | Abbvie, Chicago, IL, United States | ali.abbasi@abbvie.com | **Clinical Groups** | **Gastroenterology Group** |
| Jeffrey Waring | Abbvie, Chicago, IL, United States | jeff.waring@abbvie.com | **Clinical Groups** | **Gastroenterology Group** |
| Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | **Clinical Groups** | **Gastroenterology Group** |
| Fedik Rahimov | Abbvie, Chicago, IL, United States | fedik.rahimov@abbvie.com | **Clinical Groups** | **Gastroenterology Group** |
| Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | **Clinical Groups** | **Gastroenterology Group** |
| Tim Lu | Genentech, San Francisco, CA, United States | lut8@gene.com | **Clinical Groups** | **Gastroenterology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Gastroenterology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Gastroenterology Group** |
| Linda McCarthy | GlaxoSmithKline, Brentford, United Kingdom | linda.c.mccarthy@gsk.com | **Clinical Groups** | **Gastroenterology Group** |
| Amy Hart | Janssen Research & Development, LLC, Spring House, PA, United States | ahart13@its.jnj.com | **Clinical Groups** | **Gastroenterology Group** |
| Meijian Guan | Janssen Research & Development, LLC, Spring House, PA, United States | mguan4@its.jnj.com | **Clinical Groups** | **Gastroenterology Group** |
| Jason Miller | Merck, Kenilworth, NJ, United States | jason.miller4@merck.com | **Clinical Groups** | **Gastroenterology Group** |
| Kirsi Kalpala | Pfizer, New York, NY, United States | kirsi.kalpala@pfizer.com | **Clinical Groups** | **Gastroenterology Group** |
| Melissa Miller | Pfizer, New York, NY, United States | melissa.r.miller@pfizer.com | **Clinical Groups** | **Gastroenterology Group** |
| Xinli Hu | Pfizer, New York, NY, United States | xinli.hu@pfizer.com | **Clinical Groups** | **Gastroenterology Group** |
| Kari Eklund | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | kari.eklund@hus.fi | **Clinical Groups** | **Rheumatology Group** |
| Antti Palomäki | Hospital District of Southwest Finland, Turku, Finland | ajpalo@utu.fi | **Clinical Groups** | **Rheumatology Group** |
| Pia Isomäki | Pirkanmaa Hospital District, Tampere, Finland | pia.isomaki@pshp.fi | **Clinical Groups** | **Rheumatology Group** |
| Laura Pirilä | Hospital District of Southwest Finland, Turku, Finland | laura.pirila@fimnet.fi,laura.pirila@tyks.fi | **Clinical Groups** | **Rheumatology Group** |
| Oili Kaipiainen-Seppänen | Northern Savo Hospital District, Kuopio, Finland | oili.kaipiainen-seppanen@kuh.fi | **Clinical Groups** | **Rheumatology Group** |
| Johanna Huhtakangas | Northern Ostrobothnia Hospital District, Oulu, Finland | johanna.huhtakangas@kuh.fi | **Clinical Groups** | **Rheumatology Group** |
| Nina Mars | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | nina.mars@helsinki.fi | **Clinical Groups** | **Rheumatology Group** |
| Ali Abbasi | Abbvie, Chicago, IL, United States | ali.abbasi@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Jeffrey Waring | Abbvie, Chicago, IL, United States | jeff.waring@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Fedik Rahimov | Abbvie, Chicago, IL, United States | fedik.rahimov@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Apinya Lertratanakul | Abbvie, Chicago, IL, United States | apinya.lertratanakul@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | **Clinical Groups** | **Rheumatology Group** |
| Marla Hochfeld | Bristol Myers Squibb, New York, NY, United States | mhochfeld@celgene.com | **Clinical Groups** | **Rheumatology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Rheumatology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Rheumatology Group** |
| Jorge Esparza Gordillo | GlaxoSmithKline, Brentford, United Kingdom | jorge.x.esparza-gordillo@gsk.com | **Clinical Groups** | **Rheumatology Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Rheumatology Group** |
| Dawn Waterworth | Janssen Research & Development, LLC, Spring House, PA, United States | dwaterwo@its.jnj.com | **Clinical Groups** | **Rheumatology Group** |
| Fabiana Farias | Merck, Kenilworth, NJ, United States | fabiana.farias@merck.com | **Clinical Groups** | **Rheumatology Group** |
| Kirsi Kalpala | Pfizer, New York, NY, United States | kirsi.kalpala@pfizer.com | **Clinical Groups** | **Rheumatology Group** |
| Nan Bing | Pfizer, New York, NY, United States | nan.bing@pfizer.com | **Clinical Groups** | **Rheumatology Group** |
| Xinli Hu | Pfizer, New York, NY, United States | xinli.hu@pfizer.com | **Clinical Groups** | **Rheumatology Group** |
| Tarja Laitinen | Pirkanmaa Hospital District, Tampere, Finland | tarja.laitinen@pshp.fi | **Clinical Groups** | **Pulmonology Group** |
| Margit Pelkonen | Northern Savo Hospital District, Kuopio, Finland | margit.pelkonen@kuh.fi | **Clinical Groups** | **Pulmonology Group** |
| Paula Kauppi | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | paula.kauppi@hus.fi | **Clinical Groups** | **Pulmonology Group** |
| Hannu Kankaanranta | University of Gothenburg, Gothenburg, Sweden/ Seinäjoki Central Hospital, Seinäjoki, Finland/ Tampere University, Tampere, Finland | hannu.kankaanranta@tuni.fi | **Clinical Groups** | **Pulmonology Group** |
| Terttu Harju | Northern Ostrobothnia Hospital District, Oulu, Finland | terttu.harju@oulu.fi | **Clinical Groups** | **Pulmonology Group** |
| Riitta Lahesmaa | Hospital District of Southwest Finland, Turku, Finland | rilahes@utu.fi | **Clinical Groups** | **Pulmonology Group** |
| Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | **Clinical Groups** | **Pulmonology Group** |
| Glenda Lassi | Astra Zeneca, Cambridge, United Kingdom | glenda.lassi@astrazeneca.com | **Clinical Groups** | **Pulmonology Group** |
| Susan Eaton | Biogen, Cambridge, MA, United States | susan.eaton@biogen.com | **Clinical Groups** | **Pulmonology Group** |
| Hubert Chen | Genentech, San Francisco, CA, United States | chenh37@gene.com | **Clinical Groups** | **Pulmonology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Pulmonology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Pulmonology Group** |
| Joanna Betts | GlaxoSmithKline, Brentford, United Kingdom | joanna.c.betts@gsk.com | **Clinical Groups** | **Pulmonology Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Pulmonology Group** |
| Rajashree Mishra | GlaxoSmithKline, Brentford, United Kingdom | rajashree.x.mishra@gsk.com | **Clinical Groups** | **Pulmonology Group** |
| Majd Mouded | Novartis, Basel, Switzerland | majd.mouded@novartis.com | **Clinical Groups** | **Pulmonology Group** |
| Debby Ngo | Novartis, Basel, Switzerland | debby.ngo@novartis.com | **Clinical Groups** | **Pulmonology Group** |
| Teemu Niiranen | Finnish Institute for Health and Welfare (THL), Helsinki, Finland | teemu.niiranen@thl.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Felix Vaura | Finnish Institute for Health and Welfare (THL), Helsinki, Finland | fechva@utu.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Veikko Salomaa | Finnish Institute for Health and Welfare (THL), Helsinki, Finland | veikko.salomaa@thl.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Kaj Metsärinne | Hospital District of Southwest Finland, Turku, Finland | kaj.metsarinne@tyks.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Jenni Aittokallio | Hospital District of Southwest Finland, Turku, Finland | jemato@utu.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Mika Kähönen | Pirkanmaa Hospital District, Tampere, Finland | mika.kahonen@uta.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Jussi Hernesniemi | Pirkanmaa Hospital District, Tampere, Finland | jussi.hernesniemi@tuni.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Daniel Gordin | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | daniel.gordin@hus.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Juha Sinisalo | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | juha.sinisalo@hus.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Marja-Riitta Taskinen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | marja-riitta.taskinen@helsinki.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Tiinamaija Tuomi | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | tiinamaija.tuomi@hus.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Timo Hiltunen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | timo.hiltunen@hus.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Jari Laukkanen | Central Finland Health Care District, Jyväskylä, Finland | jari.laukkanen@ksshp.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Amanda Elliott | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA | aelliott@broadinstitute.org | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Mary Pat Reeve | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mary.reeve@helsinki.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Sanni Ruotsalainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | sanni.ruotsalainen@helsinki.fi | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Benjamin Challis | Astra Zeneca, Cambridge, United Kingdom | benjamin.challis@astrazeneca.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Dirk Paul | Astra Zeneca, Cambridge, United Kingdom | dirk.paul@astrazeneca.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Julie Hunkapiller | Genentech, San Francisco, CA, United States | hunkapiller.julie@gene.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Audrey Chu | GlaxoSmithKline, Brentford, United Kingdom | audrey.y.chu@gsk.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Dermot Reilly | Janssen Research & Development, LLC, Boston, MA, United States | dreill11@its.jnj.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Mike Mendelson | Novartis, Boston, MA, United States | mike.mendelson@novartis.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Jaakko Parkkinen | Pfizer, New York, NY, United States | jaakko.parkkinen@pfizer.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Melissa Miller | Pfizer, New York, NY, United States | melissa.r.miller@pfizer.com | **Clinical Groups** | **Cardiometabolic Diseases Group** |
| Tuomo Meretoja | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | tuomo.meretoja@hus.fi | **Clinical Groups** | **Oncology Group** |
| Heikki Joensuu | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | heikki.joensuu@hus.fi | **Clinical Groups** | **Oncology Group** |
| Olli Carpén | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | olli.carpen@helsinki.fi | **Clinical Groups** | **Oncology Group** |
| Johanna Mattson | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | johanna.mattson@hus.fi | **Clinical Groups** | **Oncology Group** |
| Eveliina Salminen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | eveliina.e.salminen@hus.fi | **Clinical Groups** | **Oncology Group** |
| Annika Auranen | Pirkanmaa Hospital District , Tampere, Finland | anaura@utu.fi | **Clinical Groups** | **Oncology Group** |
| Peeter Karihtala | Northern Ostrobothnia Hospital District, Oulu, Finland | peeter.karihtala@oulu.fi | **Clinical Groups** | **Oncology Group** |
| Päivi Auvinen | Northern Savo Hospital District, Kuopio, Finland | paivi.auvinen@kuh.fi | **Clinical Groups** | **Oncology Group** |
| Klaus Elenius | Hospital District of Southwest Finland, Turku, Finland | klaus.elenius@utu.fi | **Clinical Groups** | **Oncology Group** |
| Johanna Schleutker | Hospital District of Southwest Finland, Turku, Finland | johanna.schleutker@utu.fi | **Clinical Groups** | **Oncology Group** |
| Esa Pitkänen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | esa.pitkanen@helsinki.fi | **Clinical Groups** | **Oncology Group** |
| Nina Mars | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | nina.mars@helsinki.fi | **Clinical Groups** | **Oncology Group** |
| Mark Daly | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | **Clinical Groups** | **Oncology Group** |
| Relja Popovic | Abbvie, Chicago, IL, United States | relja.popovic@abbvie.com | **Clinical Groups** | **Oncology Group** |
| Jeffrey Waring | Abbvie, Chicago, IL, United States | jeff.waring@abbvie.com | **Clinical Groups** | **Oncology Group** |
| Bridget Riley-Gillis | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | **Clinical Groups** | **Oncology Group** |
| Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | **Clinical Groups** | **Oncology Group** |
| Jennifer Schutzman | Genentech, San Francisco, CA, United States | schutzman.jennifer@gene.com | **Clinical Groups** | **Oncology Group** |
| Julie Hunkapiller | Genentech, San Francisco, CA, United States | hunkapiller.julie@gene.com | **Clinical Groups** | **Oncology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Oncology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Oncology Group** |
| Diptee Kulkarni | GlaxoSmithKline, Brentford, United Kingdom | diptee.a.kulkarni@gsk.com | **Clinical Groups** | **Oncology Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Oncology Group** |
| Alessandro Porello | Janssen Research & Development, LLC, Spring House, PA, United States | APorrell@ITS.JNJ.com | **Clinical Groups** | **Oncology Group** |
| Andrey Loboda | Merck, Kenilworth, NJ, United States | andrey\_loboda@merck.com | **Clinical Groups** | **Oncology Group** |
| Heli Lehtonen | Pfizer, New York, NY, United States | heli.lehtonen@pfizer.com | **Clinical Groups** | **Oncology Group** |
| Stefan McDonough | Pfizer, New York, NY, United States | stefan.McDonough@pfizer.com | **Clinical Groups** | **Oncology Group** |
| Sauli Vuoti | Janssen-Cilag Oy, Espoo, Finland | svuoti@its.jnj.com | **Clinical Groups** | **Oncology Group** |
| Kai Kaarniranta | Northern Savo Hospital District, Kuopio, Finland | kai.kaarniranta@uef.fi | **Clinical Groups** | **Opthalmology Group** |
| Joni A Turunen | Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland | joni.turunen@helsinki.fi | **Clinical Groups** | **Opthalmology Group** |
| Terhi Ollila | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | terhi.ollila@hus.fi | **Clinical Groups** | **Opthalmology Group** |
| Hannu Uusitalo | Pirkanmaa Hospital District, Tampere, Finland | hannu.uusitalo@tuni.fi | **Clinical Groups** | **Opthalmology Group** |
| Juha Karjalainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | juha.karjalainen@helsinki.fi | **Clinical Groups** | **Opthalmology Group** |
| Esa Pitkänen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | esa.pitkanen@helsinki.fi | **Clinical Groups** | **Opthalmology Group** |
| Mengzhen Liu | Abbvie, Chicago, IL, United States | mengzhen.liu@abbvie.com | **Clinical Groups** | **Opthalmology Group** |
| Heiko Runz | Biogen, Cambridge, MA, United States | heiko.runz@biogen.com | **Clinical Groups** | **Opthalmology Group** |
| Stephanie Loomis | Biogen, Cambridge, MA, United States | stephanie.loomis@biogen.com | **Clinical Groups** | **Opthalmology Group** |
| Erich Strauss | Genentech, San Francisco, CA, United States | strauss.erich@gene.com | **Clinical Groups** | **Opthalmology Group** |
| Natalie Bowers | Genentech, San Francisco, CA, United States | bowersn1@gene.com | **Clinical Groups** | **Opthalmology Group** |
| Hao Chen | Genentech, San Francisco, CA, United States | haoc@gene.com | **Clinical Groups** | **Opthalmology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Opthalmology Group** |
| Kaisa Tasanen | Northern Ostrobothnia Hospital District, Oulu, Finland | kaisa.tasanen-maatta@oulu.fi | **Clinical Groups** | **Dermatology Group** |
| Laura Huilaja | Northern Ostrobothnia Hospital District, Oulu, Finland | laura.huilaja@oulu.fi | **Clinical Groups** | **Dermatology Group** |
| Katariina Hannula-Jouppi | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | katariina.hannula-jouppi@hus.fi | **Clinical Groups** | **Dermatology Group** |
| Teea Salmi | Pirkanmaa Hospital District, Tampere, Finland | teea.salmi@pshp.fi | **Clinical Groups** | **Dermatology Group** |
| Sirkku Peltonen | Hospital District of Southwest Finland, Turku, Finland | sipelto@utu.fi | **Clinical Groups** | **Dermatology Group** |
| Leena Koulu | Hospital District of Southwest Finland, Turku, Finland | leena.koulu@tyks.fi | **Clinical Groups** | **Dermatology Group** |
| Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | **Clinical Groups** | **Dermatology Group** |
| Fedik Rahimov | Abbvie, Chicago, IL, United States | fedik.rahimov@abbvie.com | **Clinical Groups** | **Dermatology Group** |
| Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | **Clinical Groups** | **Dermatology Group** |
| David Choy | Genentech, San Francisco, CA, United States | choy.david@gene.com | **Clinical Groups** | **Dermatology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Dermatology Group** |
| Dawn Waterworth | Janssen Research & Development, LLC, Spring House, PA, United States | dwaterwo@its.jnj.com | **Clinical Groups** | **Dermatology Group** |
| Kirsi Kalpala | Pfizer, New York, NY, United States | kirsi.kalpala@pfizer.com | **Clinical Groups** | **Dermatology Group** |
| Ying Wu | Pfizer, New York, NY, United States | ying.wu3@pfizer.com | **Clinical Groups** | **Dermatology Group** |
| Pirkko Pussinen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | pirkko.pussinen@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| Aino Salminen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | aino.m.salminen@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| Tuula Salo | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | tuula.salo@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| David Rice | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | david.rice@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| Pekka Nieminen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | pekka.nieminen@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| Ulla Palotie | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | ulla.palotie@helsinki.fi | **Clinical Groups** | **Odontology Group** |
| Maria Siponen | Northern Savo Hospital District, Kuopio, Finland | maria.siponen@uef.fi | **Clinical Groups** | **Odontology Group** |
| Liisa Suominen | Northern Savo Hospital District, Kuopio, Finland | liisa.suominen@uef.fi | **Clinical Groups** | **Odontology Group** |
| Päivi Mäntylä | Northern Savo Hospital District, Kuopio, Finland | paivi.mantyla@uef.fi | **Clinical Groups** | **Odontology Group** |
| Ulvi Gursoy | Hospital District of Southwest Finland, Turku, Finland | ulvi.gursoy@utu.fi | **Clinical Groups** | **Odontology Group** |
| Vuokko Anttonen | Northern Ostrobothnia Hospital District, Oulu, Finland | vuokko.anttonen@oulu.fi | **Clinical Groups** | **Odontology Group** |
| Kirsi Sipilä | Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland; Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland | kirsi.sipila@oulu.fi | **Clinical Groups** | **Odontology Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | pendergrass.sarah@gene.com | **Clinical Groups** | **Odontology Group** |
| Hannele Laivuori | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hannele.laivuori@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Venla Kurra | Pirkanmaa Hospital District, Tampere, Finland | venla.kurra@tuni.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Laura Kotaniemi-Talonen | Pirkanmaa Hospital District, Tampere, Finland | laura.kotaniemi-talonen@tuni.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Oskari Heikinheimo | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | oskari.heikinheimo@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Ilkka Kalliala | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | ilkka.kalliala@hus.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Lauri Aaltonen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | lauri.aaltonen@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Varpu Jokimaa | Hospital District of Southwest Finland, Turku, Finland | varpu.jokimaa@utu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Johannes Kettunen | Northern Ostrobothnia Hospital District, Oulu, Finland | Johannes.Kettunen@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Marja Vääräsmäki | Northern Ostrobothnia Hospital District, Oulu, Finland | marja.vaarasmaki@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Outi Uimari | Northern Ostrobothnia Hospital District, Oulu, Finland | outi.uimari@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Laure Morin-Papunen | Northern Ostrobothnia Hospital District, Oulu, Finland | lmp@cc.oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Maarit Niinimäki | Northern Ostrobothnia Hospital District, Oulu, Finland | maarit.niinimaki@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Terhi Piltonen | Northern Ostrobothnia Hospital District, Oulu, Finland | terhi.piltonen@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Katja Kivinen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | katja.kivinen@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Elisabeth Widen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | elisabeth.widen@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Taru Tukiainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | taru.tukiainen@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Mary Pat Reeve | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mary.reeve@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Mark Daly | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Niko Välimäki | University of Helsinki, Helsinki, Finland | niko.valimaki@helsinki.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Eija Laakkonen | University of Jyväskylä, Jyväskylä, Finland | eija.k.laakkonen@jyu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Jaakko Tyrmi | University of Oulu, Oulu, Finland / University of Tampere, Tampere, Finland | jaakko.tyrmi@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Heidi Silven | University of Oulu, Oulu, Finland | heidi.silven@student.oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Eeva Sliz | University of Oulu, Oulu, Finland | eeva.sliz@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Riikka Arffman | University of Oulu, Oulu, Finland | riikka.arffman@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Susanna Savukoski | University of Oulu, Oulu, Finland | susanna.savukoski@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Triin Laisk | Estonian biobank, Tartu, Estonia | triin.laisk@ut.ee | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Natalia Pujol | Estonian biobank, Tartu, Estonia | natalia.pujolgualdo@oulu.fi | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Mengzhen Liu | Abbvie, Chicago, IL, United States | mengzhen.liu@abbvie.com | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Bridget Riley-Gillis | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Janet Kumar | GlaxoSmithKline, Collegeville, PA, United States | janet.x.kumar@gsk.com | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | **Clinical Groups** | **Women’s Health and Reproduction Group** |
| Iiris Hovatta | University of Helsinki, Finland | iiris.hovatta@helsinki.fi | **Clinical Groups** | **Depression group** |
| Chia-Yen Chen | Biogen, Cambridge, MA, United States | chiayen.chen@biogen.com | **Clinical Groups** | **Depression group** |
| Erkki Isometsä | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | erkki.isometsa@hus.fi | **Clinical Groups** | **Depression group** |
| Hanna Ollila | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hanna.m.ollila@helsinki.fi | **Clinical Groups** | **Depression group** |
| Jaana Suvisaari | Finnish Institute for Health and Welfare (THL), Helsinki, Finland | jaana.suvisaari@thl.fi | **Clinical Groups** | **Depression group** |
| Thomas Damm Als | Aarhus University, Denmark | tda@biomed.au.dk | **Clinical Groups** | **Depression group** |
| Antti Mäkitie | Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland | antti.makitie@helsinki.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Argyro Bizaki-Vallaskangas | Pirkanmaa Hospital District, Tampere, Finland | argyro.bizaki-vallaskangas@tuni.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Sanna Toppila-Salmi | University of Helsinki, Finland | sanna.salmi@helsinki.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Tytti Willberg | Hospital District of Southwest Finland, Turku, Finland | tytti.willberg@tyks.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Elmo Saarentaus | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | elmo.saarentaus@helsinki.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Antti Aarnisalo | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | antti.aarnisalo@hus.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Eveliina Salminen | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | eveliina.e.salminen@hus.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Elisa Rahikkala | Northern Ostrobothnia Hospital District, Oulu, Finland | elisa.rahikkala@ppshp.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Johannes Kettunen | Northern Ostrobothnia Hospital District, Oulu, Finland | johannes.kettunen@oulu.fi | **Clinical Groups** | **ENT (ear, nose and throath) Group** |
| Kristiina Aittomäki | Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland | kristiina.aittomaki@helsinki.fi | **Clinical Groups** | **POI (premature ovarian failure) Group** |
| Fredrik Åberg | Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland | fredrik.aberg@helsinki.fi | **Clinical Groups** | **LiverScore Group** |
| Mitja Kurki | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States | mkurki@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Samuli Ripatti | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | samuli.ripatti@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Mark Daly | Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Juha Karjalainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | juha.karjalainen@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Aki Havulinna | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Finnish Institute for Health and Welfare (THL), Helsinki, Finland | aki.havulinna@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Juha Mehtonen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | juha.mehtonen@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Priit Palta | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | priit.palta@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Shabbeer Hassan | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | shabbeer.hassan@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Pietro Della Briotta Parolo | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | pietro.dellabriottaparolo@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Wei Zhou | Broad Institute, Cambridge, MA, United States | wzhou@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Mutaamba Maasha | Broad Institute, Cambridge, MA, United States | mmaasha@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Shabbeer Hassan | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | shabbeer.hassan@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Susanna Lemmelä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | susanna.lemmela@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Manuel Rivas | University of Stanford, Stanford, CA, United States | mrivas@stanford.edu | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Mari E. Niemi | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mari.e.niemi@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Aarno Palotie | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | aarno.palotie@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Aoxing Liu | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | aoxing.liu@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Arto Lehisto | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | arto.lehisto@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Andrea Ganna | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | aganna@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Vincent Llorens | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | vincent.llorens@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Hannele Laivuori | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hannele.laivuori@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Taru Tukiainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | taru.tukiainen@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Mary Pat Reeve | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mary.reeve@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Henrike Heyne | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hheyne@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Nina Mars | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | nina.mars@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Joel Rämö | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | joel.ramo@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Elmo Saarentaus | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | elmo.saarentaus@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Hanna Ollila | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hanna.m.ollila@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Rodos Rodosthenous | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | rodos.rodosthenous@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Satu Strausz | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | satu.strausz@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Tuula Palotie | University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland | tuula.palotie@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Kimmo Palin | University of Helsinki, Helsinki, Finland | kimmo.palin@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Javier Garcia-Tabuenca | University of Tampere, Tampere, Finland | javier.graciatabuenca@tuni.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Harri Siirtola | University of Tampere, Tampere, Finland | harri.siirtola@tuni.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Tuomo Kiiskinen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | tuomo.kiiskinen@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Jiwoo Lee | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States | jiwoo.lee@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Kristin Tsuo | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States | kristintsuo@fas.harvard.edu | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Amanda Elliott | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA | aelliott@broadinstitute.org | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Kati Kristiansson | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | kati.kristiansson@thl.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Mikko Arvas | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | mikko.arvas@veripalvelu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Kati Hyvärinen | Finnish Red Cross Blood Service, Helsinki, Finland | kati.hyvarinen@veripalvelu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Jarmo Ritari | Finnish Red Cross Blood Service, Helsinki, Finland | jarmo.ritari@veripalvelu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Olli Carpén | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | olli.carpen@helsinki.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Johannes Kettunen | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | johannes.kettunen@oulu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Katri Pylkäs | University of Oulu, Oulu, Finland | katri.pylkas@oulu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Eeva Sliz | University of Oulu, Oulu, Finland | eeva.sliz@oulu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Minna Karjalainen | University of Oulu, Oulu, Finland | minna.k.karjalainen@oulu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Tuomo Mantere | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | tuomo.mantere@oulu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Eeva Kangasniemi | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | eeva.kangasniemi@pshp.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Sami Heikkinen | University of Eastern Finland, Kuopio, Finland | sami.heikkinen@uef.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Arto Mannermaa | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | arto.mannermaa@uef.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Eija Laakkonen | University of Jyväskylä, Jyväskylä, Finland | eija.k.laakkonen@jyu.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Nina Pitkänen | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | Niina.Pitkanen@tyks.fi | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Samuel Lessard | Translational Sciences, Sanofi R&D, Framingham, MA, USA | samuel.lessard@sanofi.com | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Clément Chatelain | Translational Sciences, Sanofi R&D, Framingham, MA, USA | clement.chatelain@sanofi.com | **FinnGen Analysis working group** | **FinnGen Analysis working group** |
| Perttu Terho | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | perttu.terho@tyks.fi | **Biobank directors** | **Biobank directors** |
| Sirpa Soini | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | sirpa.soini@thl.fi | **Biobank directors** | **Biobank directors** |
| Jukka Partanen | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | jukka.partanen@veripalvelu.fi | **Biobank directors** | **Biobank directors** |
| Eero Punkka | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | eero.punkka@hus.fi | **Biobank directors** | **Biobank directors** |
| Raisa Serpi | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | raisa.serpi@ppshp.fi | **Biobank directors** | **Biobank directors** |
| Sanna Siltanen | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | sanna.siltanen@pshp.fi | **Biobank directors** | **Biobank directors** |
| Veli-Matti Kosma | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | veli-matti.kosma@uef.fi | **Biobank directors** | **Biobank directors** |
| Teijo Kuopio | Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland | teijo.kuopio@ksshp.fi | **Biobank directors** | **Biobank directors** |
| Anu Jalanko | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | anu.jalanko@helsinki.fi | **FinnGen Teams** | **Administration** |
| Huei-Yi Shen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | huei-yi.shen@helsinki.fi | **FinnGen Teams** | **Administration** |
| Risto Kajanne | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | risto.kajanne@helsinki.fi | **FinnGen Teams** | **Administration** |
| Mervi Aavikko | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mervi.aavikko@helsinki.fi | **FinnGen Teams** | **Administration** |
| Henna Palin | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | henna.palin@pshp.fi | **FinnGen Teams** | **Administration** |
| Malla-Maria Linna | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | malla-maria.linna@hus.fi | **FinnGen Teams** | **Administration** |
| Mitja Kurki | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States | mkurki@broadinstitute.org | **FinnGen Teams** | **Analysis** |
| Juha Karjalainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | juha.karjalainen@helsinki.fi | **FinnGen Teams** | **Analysis** |
| Pietro Della Briotta Parolo | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | pietro.dellabriottaparolo@helsinki.fi | **FinnGen Teams** | **Analysis** |
| Arto Lehisto | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | arto.lehisto@helsinki.fi | **FinnGen Teams** | **Analysis** |
| Juha Mehtonen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | juha.mehtonen@helsinki.fi | **FinnGen Teams** | **Analysis** |
| Wei Zhou | Broad Institute, Cambridge, MA, United States | wzhou@broadinstitute.org | **FinnGen Teams** | **Analysis** |
| Masahiro Kanai | Broad Institute, Cambridge, MA, United States | mkanai@broadinstitute.org | **FinnGen Teams** | **Analysis** |
| Mutaamba Maasha | Broad Institute, Cambridge, MA, United States | mmaasha@broadinstitute.org | **FinnGen Teams** | **Analysis** |
| Hannele Laivuori | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | hannele.laivuori@helsinki.fi | **FinnGen Teams** | **Clinical Endpoint Development** |
| Aki Havulinna | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Finnish Institute for Health and Welfare (THL), Helsinki, Finland | aki.havulinna@helsinki.fi | **FinnGen Teams** | **Clinical Endpoint Development** |
| Susanna Lemmelä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | susanna.lemmela@helsinki.fi | **FinnGen Teams** | **Clinical Endpoint Development** |
| Tuomo Kiiskinen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | tuomo.kiiskinen@helsinki.fi | **FinnGen Teams** | **Clinical Endpoint Development** |
| L. Elisa Lahtela | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | laura.lahtela@helsinki.fi | **FinnGen Teams** | **Clinical Endpoint Development** |
| Mari Kaunisto | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mari.kaunisto@helsinki.fi | **FinnGen Teams** | **Communication** |
| Elina Kilpeläinen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | elina.kilpelainen@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Timo P. Sipilä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | timo.p.sipila@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Oluwaseun Alexander Dada | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | alexander.dada@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Awaisa Ghazal | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | awaisa.ghazal@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Anastasia Kytölä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | anastasia.shcherban@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Rigbe Weldatsadik | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | rigbe.weldatsadik@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Sanni Ruotsalainen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | sanni.ruotsalainen@helsinki.fi | **FinnGen Teams** | **E-Science** |
| Kati Donner | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | kati.donner@helsinki.fi | **FinnGen Teams** | **Genotyping** |
| Timo P. Sipilä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | timo.p.sipila@helsinki.fi | **FinnGen Teams** | **Genotyping** |
| Anu Loukola | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | anu.loukola@hus.fi | **FinnGen Teams** | **Sample Collection Coordination** |
| Päivi Laiho | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | paivi.laiho@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Tuuli Sistonen | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | tuuli.sistonen@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Essi Kaiharju | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | essi.kaiharju@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Markku Laukkanen | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | markku.laukkanen@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Elina Järvensivu | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | elina.jarvensivu@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Sini Lähteenmäki | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | sini.lahteenmaki@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Lotta Männikkö | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | lotta.mannikko@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Regis Wong | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | regis.wong@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Auli Toivola | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | auli.toivola@thl.fi | **FinnGen Teams** | **Sample Logistics** |
| Minna Brunfeldt | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | minna.brunfeldt@thl.fi | **FinnGen Teams** | **Registry Data Operations** |
| Hannele Mattsson | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | hannele.mattsson@thl.fi | **FinnGen Teams** | **Registry Data Operations** |
| Kati Kristiansson | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | kati.kristiansson@thl.fi | **FinnGen Teams** | **Registry Data Operations** |
| Susanna Lemmelä | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | susanna.lemmela@helsinki.fi | **FinnGen Teams** | **Registry Data Operations** |
| Sami Koskelainen | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | sami.koskelainen@thl.fi | **FinnGen Teams** | **Registry Data Operations** |
| Tero Hiekkalinna | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | tero.hiekkalinna@helsinki.fi | **FinnGen Teams** | **Registry Data Operations** |
| Teemu Paajanen | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | teemu.paajanen@thl.fi | **FinnGen Teams** | **Registry Data Operations** |
| Priit Palta | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | priit.palta@helsinki.fi | **FinnGen Teams** | **Sequencing Informatics** |
| Kalle Pärn | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | kalle.parn@helsinki.fi | **FinnGen Teams** | **Sequencing Informatics** |
| Mart Kals | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mart.kals@helsinki.fi | **FinnGen Teams** | **Sequencing Informatics** |
| Shuang Luo | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | shuang.luo@helsinki.fi | **FinnGen Teams** | **Sequencing Informatics** |
| Tarja Laitinen | Pirkanmaa Hospital District, Tampere, Finland | tarja.laitinen@pshp.fi | **FinnGen Teams** | **Trajectory** |
| Mary Pat Reeve | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | mary.reeve@helsinki.fi | **FinnGen Teams** | **Trajectory** |
| Shanmukha Sampath Padmanabhuni | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | sam.padmanabhuni@helsinki.fi | **FinnGen Teams** | **Trajectory** |
| Marianna Niemi | University of Tampere, Tampere, Finland | marianna.niemi@tuni.fi | **FinnGen Teams** | **Trajectory** |
| Harri Siirtola | University of Tampere, Tampere, Finland | harri.siirtola@tuni.fi | **FinnGen Teams** | **Trajectory** |
| Javier Gracia-Tabuenca | University of Tampere, Tampere, Finland | javier.graciatabuenca@tuni.fi | **FinnGen Teams** | **Trajectory** |
| Mika Helminen | University of Tampere, Tampere, Finland | mika.helminen@tuni.fi | **FinnGen Teams** | **Trajectory** |
| Tiina Luukkaala | University of Tampere, Tampere, Finland | tiina.luukkaala@tuni.fi | **FinnGen Teams** | **Trajectory** |
| Iida Vähätalo | University of Tampere, Tampere, Finland | iida.vahatalo@epshp.fi | **FinnGen Teams** | **Trajectory** |
| Jyrki Pitkänen | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | jyrki.pitkanen@helsinki.fi | **FinnGen Teams** | **Data protection officer** |
| Marco Hautalahti | Finnish Biobank Cooperative - FINBB | marco.hautalahti@finbb.fi | **FinnGen Teams** | **FINBB - Finnish biobank cooperative** |
| Johanna Mäkelä | Finnish Biobank Cooperative - FINBB | johanna.makela@finbb.fi | **FinnGen Teams** | **FINBB - Finnish biobank cooperative** |
| Sarah Smith | Finnish Biobank Cooperative - FINBB | sarah.smith@finbb.fi | **FinnGen Teams** | **FINBB - Finnish biobank cooperative** |
| Tom Southerington | Finnish Biobank Cooperative - FINBB | tom.southerington@finbb.fi | **FinnGen Teams** | **FINBB - Finnish biobank cooperative** |

**SUPPLEMENTARY TABLES AND FIGURES**

**Supplementary Table 1. Summary of ALS case-control analysis results (HRE carriers excluded), comparison of tagging SNP and intermediate-length allele analyses**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| SNP  (present study) | 504 cases  n (%) | 3190 controls  n (%) | p | OR | 95 % CI |
| rs2814707\*T carrier | 180 (35.7%) | 1002 (31.4%) | 0.057 | 1.21 | 0.99-1.48 |
| rs139185008\*C carrier | 30 (6.0 %) | 91 (2.9%) | 0.0010 | 2.15 | 1.36-3.33 |
| rs2814707\*T homozygous | 25 (5.0%) | 88 (2.8%) | 0.012 | 1.84 | 1.17-2.90 |
| rs2814707\*T homozygous  rs139185008\*C carrier | 11 (2.2%) | 14 (0.4%) | 0.00020 | 5.06 | 2.06-12.07 |
| rs2814707\*T homozygous  no rs139185008\*C | 14 (2.8%) | 74 (2.3%) | 0.53 | 1.20 | 0.62-2.17 |
| Intermediate-length alleles  (from ref. 16) | **525 cases**  **n (%)** | **3950 controls**  **n (%)** |  |  |  |
| ≥7 carrier | 185 (35.2%) | 1293 (32.7%) | 0.26 | 1.12 | 0.92–1.36 |
| 17–45 carrier | 19 (3.6%) | 101 (2.6%) | 0.15 | 1.43 | 0.82–2.74 |
| 21–45 carrier | 12 (2.3%) | 66 (1.7%) | 0.29 | 1.38 | 0.67–2.59 |
| ≥7/≥7 | 26 (5.0%) | 104 (2.6%) | 0.005 | 1.93 | 1.19–3.02 |
| ≥7/17–45 | 7 (1.3%) | 10 (0.25%) | 0.002 | 5.32 | 1.71–15.56 |
| ≥7/21–45 | 6 (1.1%) | 3 (0.076%) | 0.00016 | 15.19 | 3.23–94.21 |
| 7–16/7–16 | 19 (3.6%) | 94 (2.4%) | 0.098 | 1.57 | 0.90– 2.62 |

HRE=Hexanucleotide repeat expansion. rs139185008\*C carriers among ALS cases (n=30) include 15 cases without any intermediate-length alleles, these samples may have hidden non-genotyped HREs or SNP imputation errors.

**Supplementary Table 2. Demographic details of final study cohorts**

|  |  |  |
| --- | --- | --- |
|  | **ALS** | **Controls** |
| **N** | 683\* | 3196\* |
| **Male (%)** | 327 (49,38%) | 1568 (49.1%) |
| **Mean age** | 63,4 | 75.2 |
| **Median age** | 63 | 75 |
| **Age of onset - mean** | 58,3 | - |
| **Age of onset - median** | 59 | - |
| **Site of onset** |  | - |
| **Bulbar (%)** | 225 (33,99 %) | - |
| **Lower (%)** | 240 (36,25 %) | - |
| **Upper (%)** | 162 (24,47 %) | - |
| **Limb (%)** | 10 (1,51 %) | - |
| **Resp (%)** | 9 (1,36 %) | - |
| **NA (%)** | 14 (2,27 %) | - |

\*Exact demographic data missing in 23 ALS cases and 6 controls and were excluded in demographic detail calculations

**Supplementary Table 3. Genotype concordance between AmplideX C9orf72 kit and RP-PCR.**


|  |  |  |  |
| --- | --- | --- | --- |
| Sample |  | Amplidex genotype (manually checked genotypes when genotype missing or mismatching) | RP-PCR genotype |
| A14LIALS101 |  | 2, >145 | 2/exp |
| A14LIALS15 |  | 8, 8 (8/10) | 8/10 |
| A14LIALS169 |  | 2, 2 (2/exp) | 2/exp |
| A14LIALS187 |  | 8, 35 | 8/36 |
| A14LIALS236 |  | 2, 19 | 2/19 |
| A14LIALS26 |  | 8, 22 | 8/22 |
| A14LIALS272 |  | 2, 36 | 2/37 |
| A14LIALS279 |  | 2, 11 | 2/11 |
| A14LIALS283 |  | 2, 19 | 2/19 |
| A14LIALS285 |  | 2, 12 (2/12) | 12/12\* |
| A14LIALS300 |  | 2, >145 | 2/exp |
| A14LIALS301 |  | 2, >145 | 2/exp |
| A14LIALS303 |  | 2, >145 | 2/exp |
| A14LIALS312 |  | 2, 2 (2/exp) | 2/exp |
| A14LIALS391 |  | 5, 15 | 5/15 |
| A14LIALS405 |  | 2, 14 | 2/14 |
| A14LIALS45 |  | (2/36) | 2/37 |
| A14LIALS452 |  | 8, 22, 41 | 8/22\* |
| A14LIALS58 |  | 5, >145 | 5/exp |
| A14LIALS66 |  | (2/exp) | 2/exp |
| N19ALS172 |  | 2, >145 | 2/exp |
| N19ALS176 |  | 5, >145 | 5/exp |
| N19ALS187 |  | 2, >145 | 2/exp |
| N19ALS20 |  | 7, 16, 34 (7/16) | 7/16 |
| N19ALS225 |  | 2, >145 | 2/exp |
| N19ALS254 |  | (2/exp) | 2/exp |
| N19ALS326 |  | 2, >145 | 2/exp |
| N19ALS337 |  | 10, 18 | 10/18 |
| N19ALS35 |  | 2, 22 | 2/22 |
| N19ALS43 |  | 5, 23 | 5/23 |
| N19ALS53 |  | 8, 10 | 8/10 |
| S14F13ALS19 |  | 7, 24 | 7/24 |
| S14F13ALS37 |  | 2, 2, >145 (2/145) | 2/exp |
| S14F13ALS45 |  | 2, >145 | 2/exp |
| S14F13ALS54 |  | 8, >145 | 8/exp |
| S14F13ALS62 |  | 8, 8 (8/13) | 8/13 |
| S14F13ALS77 |  | 2, 45 (2/42-48) | 2/exp |
| S14F13ALS79 |  | 5, >145 | 5/exp |
| S14F13ALS8 |  | 8, >145 | 8/exp |
| S14F13ALS80 |  | 2, >145 | 2/exp |

\*Genotype confirmed with over-the-repeat PCR

**Supplementary Figure 1. Statistical power of SNP regression analyses in FinnGen.**

(A) Total sample number needed for 80 % power with different effect sizes (odds ratios) for rs139185008 heterozygosity analysis (MAF 1.3 %, dominant model, binary outcome, case rate 3%). (B) Total sample number needed for 80 % power with different effect sizes (odds ratios) for rs2814707 homozygosity analysis (MAF 17 %, recessive model, binary outcome). Sample size was calculated with genpwr R package.

**A**



**B**

